KRAS<sup>G12C</sup>抑制剂在晚期结直肠癌治疗中的研究进展

摘要/Abstract

摘要：

结直肠癌（CRC）是全球癌症相关死亡的主要原因之一。30%~40%的转移性CRC患者会发生KRAS基因突变，从而导致患者对抗表皮生长因子受体存在耐药性并且预后较差。针对KRAS的靶向治疗一直是研究的热点。近年来，KRAS^G12C突变抑制剂在实体瘤治疗中取得了良好的疗效。KRAS^G12C抑制剂可作为单一疗法或联合其他靶点抑制剂应用于KRAS^G12C突变转移性CRC。分析KRAS^G12C抑制剂在CRC中的研究进展具有重要意义，可为指导晚期CRC治疗提供参考。

关键词:结直肠肿瘤,KRAS^G12C抑制剂,分子靶向治疗

Abstract:

Colorectal cancer （CRC） remains a leading cause of cancer mortality globally. Mutations of the KRAS gene occur in 30%-40% of metastatic colorectal cancer patients， contributing to resistance to anti-epidermal growth factor receptor therapy and poor prognosis. Targeted therapy for KRAS has always been a research hotspot. In recent years， KRAS^G12Cmutation inhibitors have achieved good efficacy in the treatment of solid tumors. KRAS^G12Cinhibitors can be used as monotherapies and in combination with other targeted inhibitors for metastatic KRAS^G12C-mutant colorectal cancer. Analyzing the research progress of KRAS^G12Cinhibitors in CRC is of great significance and can provide reference for guiding the treatment of advanced CRC.

Key words:Colorectal neoplasms,KRAS^G12Cinhibitors,Molecular targete therapy

吴鑫, 任海朋. KRAS^G12C抑制剂在晚期结直肠癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(8): 538-542.

Wu Xin, Ren Haipeng. Research progress of KRAS^G12Cinhibitors in the treatment of advanced colorectal cancer[J]. Journal of International Oncology, 2025, 52(8): 538-542.

参考文献39

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3): 229-263. DOI:10.3322/caac.21834.
[2]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J].CA Cancer J Clin,2022,72(1): 7-33. DOI:10.3322/caac.21708.
[3]	Henry JT, Coker O, Chowdhury S, et al. Comprehensive clinical and molecular characterization of KRAS^G12C-mutant colorectal cancer[J].JCO Precis Oncol,2021, 5: PO. 20.00256. DOI:10.1200/PO.20.00256.
[4]	Loong HH, Du N, Cheng C, et al. KRAS^G12Cmutations in Asia: a landscape analysis of 11,951 Chinese tumor samples[J].Transl Lung Cancer Res,2020,9(5): 1759-1769. DOI:10.21037/tlcr-20-455.
[5]	Hong DS, Fakih MG, Strickler JH, et al. KRAS^G12Cinhibition with sotorasib in advanced solid tumors[J].N Engl J Med,2020,383(13): 1207-1217. DOI:10.1056/NEJMoa1917239.
[6]	Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS^G12C[J].N Engl J Med,2023,388(1): 44-54. DOI:10.1056/NEJMoa2212419.
[7]	Jiang J, Jiang L, Maldonato BJ, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers[J].Cancer Discov,2024,14(6): 994-1017. DOI:10.1158/2159-8290.CD-24-0027.
[8]	Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance[J].J Cell Sci,2016,129(7): 1287-1292. DOI:10.1242/jcs.182873. pmid:26985062
[9]	Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease[J].Cell,2017,170(4): 605-635. DOI:10.1016/j.cell.2017.07.029. pmid:28802037
[10]	Yuan TL, Amzallag A, Bagni R, et al. Differential effector engagement by oncogenic KRAS[J].Cell Rep,2018,22(7): 1889-1902. DOI:10.1016/j.celrep.2018.01.051. pmid:29444439
[11]	Takeda M, Yoshida S, Inoue T, et al. The role of KRAS mutations in colorectal cancer: biological insights, clinical implications, and future therapeutic perspectives[J].Cancers (Basel),2025,17(3): 428. DOI:10.3390/cancers17030428.
[12]	Papke B, Der CJ. Drugging RAS: know the enemy[J].Science,2017,355(6330): 1158-1163. DOI:10.1126/science.aam7622. pmid:28302824
[13]	Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions[J].Nature,2013,503(7477): 548-551. DOI:10.1038/nature12796.
[14]	Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: activity and resistance[J].Cancer Gene Ther,2022,29(7): 875-878. DOI:10.1038/s41417-021-00383-9.
[15]	Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRAS^G12Cmutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial[J].Lancet Oncol,2022,23(1): 115-124. DOI:10.1016/S1470-2045(21)00605-7.
[16]	Ou SI, Jänne PA, Leal TA, et al. First-in-human phase Ⅰ/ⅠB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS^G12Csolid tumors (KRYSTAL-1)[J].J Clin Oncol,2022,40(23): 2530-2538. DOI:10.1200/JCO.21.02752.
[17]	Hallin J, Engstrom LD, Hargis L, et al. The KRAS^G12Cinhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients[J].Cancer Discov,2020,10(1): 54-71. DOI:10.1158/2159-8290.CD-19-1167. pmid:31658955
[18]	Sacher A, LoRusso P, Patel MR, et al. Single-agent divarasib(GDC-6036) in solid tumors with a KRAS^G12Cmutation[J].N Engl J Med,2023,389(8): 710-721. DOI:10.1056/NEJMoa2303810.
[19]	Zhou Q, Meng X, Sun L, et al. Efficacy and safety of KRAS^G12Cinhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study[J].J Thorac Oncol,2024,19(12): 1630-1639. DOI:10.1016/j.jtho.2024.08.005.
[20]	ClinicalTrials. Gov. An open-label, multi-center phase Ⅰ/Ⅱ clinical study evaluating the safety/tolerability, pharmacokinetics, and effectiveness of GFH925 in patients with advanced solid tumors with KRAS^G12Cmutations[EB/OL]. [2024-11-26] [2025-04-08]. https://adisinsight.springer.com/trials/700341538.
[21]	ClinicalTrials. Gov. An open-label, multicenter, phase Ⅰb/Ⅲ study of efficacy and safety of IBI351 in combination with cetuximab in subjects with KRAS^G12Cmutated metastatic colorectal cancer[EB/OL]. [2022-09-30] [2025-04-08]. https://clinicaltrials.gov/study/NCT05497336?term=NCT05497336&rank=1.
[22]	Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRAS^G12Cinhibition in colorectal cancer[J].Cancer Discov,2020,10(8): 1129-1139. DOI:10.1158/2159-8290.CD-20-0187. pmid:32430388
[23]	Yaeger R, Mezzadra R, Sinopoli J, et al. Molecular characterization of acquired resistance to KRAS^G12C-EGFR inhibition in colorectal cancer[J].Cancer Discov,2023,13(1): 41-55. DOI:10.1158/2159-8290.CD-22-0405.
[24]	Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS^G12C[J].N Engl J Med,2023,389(23): 2125-2139. DOI:10.1056/NEJMoa2308795.
[25]	Yaeger R, Uboha NV, Pelster MS, et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRAS^G12C-mutated metastatic colorectal cancer[J].Cancer Discov,2024,14(6): 982-993. DOI:10.1158/2159-8290.CD-24-0217. pmid:38587856
[26]	Desai J, Alonso G, Kim SH, et al. Divarasib plus cetuximab in KRAS^G12C-positive colorectal cancer: a phase 1b trial[J].Nat Med,2024,30(1): 271-278. DOI:10.1038/s41591-023-02696-8.
[27]	ClinicalTrials. Gov. A phase 1/1b trial of MRTX849 in combination with BI 1701963 in patients with advanced solid tumors with KRAS^G12Cmutation[EB/OL]. [2024-12-16] [2025-02-28]. https://clinicaltrials.gov/study/NCT04975256?term=NCT04975256&rank=1.
[28]	ClinicalTrials. Gov. A phase 1/2 trial of MRTX849 in combination with TNO155 in patients with advanced solid tumors with KRAS^G12Cmutation KRYSTAL 2[EB/OL]. [2025-04-04] [2025-04-07]. https://clinicaltrials.gov/study/NCT04330664?term=NCT04330664&rank=1.
[29]	ClinicalTrials. Gov. Phase Ⅰ trial of adagrasib (MRTX849) in combination with cetuximab and irinotecan in patients with colorectal cancer[EB/OL]. [2025-03-10] [2025-04-07]. https://clinicaltrials.gov/study/NCT05722327?term=NCT05722327&rank=1.
[30]	ClinicalTrials. Gov. Study of sotorasib, panitumumab and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for treatment-naïve subjects with metastatic colorectal cancer with KRAS p.G12C mutation (CodeBreaK 301)[EB/OL]. [2025-04-04] [2025-04-07]. https://clinicaltrials.gov/study/NCT06252649?term=NCT06252649&rank=1.
[31]	Zhang J, Lim SM, Yu MR, et al. D3S-001, a KRAS^G12Cinhibitor with rapid target engagement kinetics, overcomes nucleotide cycling, and demonstrates robust preclinical and clinical activities[J].Cancer Discov,2024,14(9): 1675-1698. DOI:10.1158/2159-8290.CD-24-0006.
[32]	ClinicalTrials. Gov. A Phase 1/2, open label, dose-escalation, and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S 001 monotherapy or combination therapy in subjects with advanced solid tumors with a KRAS p.G12C mutation[EB/OL]. [2025-04-08] [2025-04-08]. https://clinicaltrials.gov/study/NCT05410145?term=NCT05410145&rank=1.
[33]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J].国际肿瘤学杂志,2024,51(2): 95-98. DOI:10.3760/cma.j.cn371439-20231008-00013.
[34]	Stickler S, Rath B, Hamilton G. Targeting KRAS in pancreatic cancer[J].Oncol Res,2024,32(5): 799-805. DOI:10.32604/or.2024.045356. pmid:38686056
[35]	Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms[J].J Hematol Oncol,2024,17(1): 108. DOI:10.1186/s13045-024-01631-9.
[36]	Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS^G12Cinhibition in cancer[J].N Engl J Med,2021,384(25): 2382-2393. DOI:10.1056/NEJMoa2105281.
[37]	Ryan MB, Coker O, Sorokin A, et al. KRAS^G12C-independent feedback activation of wild-type RAS constrains KRAS^G12Cinhibitor efficacy[J].Cell Rep,2022,39(12): 110993. DOI:10.1016/j.celrep.2022.110993.
[38]	Paniagua G, Jacob HKC, Brehey O, et al. KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors[J].Mol Oncol,2022,16(17): 3066-3081. DOI:10.1002/1878-0261.13213.
[39]	Hu F, Lito P. Insights into how adeno-squamous transition drives KRAS inhibitor resistance[J].Cancer Cell,2024,42(3): 330-332. DOI:10.1016/j.ccell.2024.02.014. pmid:38471455

KRAS^G12C抑制剂在晚期结直肠癌治疗中的研究进展

Research progress of KRAS^G12Cinhibitors in the treatment of advanced colorectal cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献39

相关文章15

编辑推荐

Metrics

本文评价

[1]	陈俊, 唐丹丹, 周雨馨, 谭玉婷, 李泓澜, 徐群, 项永兵.1990—2021年中国中青年结直肠癌疾病负担时间趋势分析[J]. 国际肿瘤学杂志, 2025, 52(8): 508-516.
[2]	钟啸, 李步托, 王琳琳.ALK阳性NSCLC脑转移放疗的研究进展[J]. 国际肿瘤学杂志, 2025, 52(6): 374-378.
[3]	袁纯, 于雪松, 王孟超, 张韶, 黄彦博, 王超然, 孔凡铭, 陈立伟.EGFR ex20ins突变型晚期NSCLC靶向治疗新进展[J]. 国际肿瘤学杂志, 2025, 52(6): 382-387.
[4]	王勇, 乌新林.结直肠癌肝转移的相关分子机制[J]. 国际肿瘤学杂志, 2025, 52(6): 388-391.
[5]	郭海洋, 洪永刚, 郝立强.铁死亡在结直肠癌中的作用及研究进展[J]. 国际肿瘤学杂志, 2025, 52(5): 319-324.
[6]	.结直肠癌筛查与早诊早治方案（2024年版）[J]. 国际肿瘤学杂志, 2025, 52(4): 195-196.
[7]	唐磊, 蔡宗佑, 常建华.RET原癌基因与非小细胞肺癌的研究现状[J]. 国际肿瘤学杂志, 2025, 52(4): 237-241.
[8]	魏毓正, 温馨格, 孙诚诚, 范秉杰, 丛蕾.分子靶向治疗EGFR基因突变和ALK基因融合肺腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2025, 52(4): 249-252.
[9]	王逸, 王强力, 张甲, 杨懿瑾, 王盛.结直肠癌肝转移患者组织中SUCNR1和YBX1的表达与临床病理特征及预后的关系[J]. 国际肿瘤学杂志, 2025, 52(3): 152-157.
[10]	叶永英, 邹艳, 陈天明, 吴伟莉.时钟基因Period家族在头颈鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(2): 113-118.
[11]	黄镇, 晏菲, 马燕凌, 孙建海.食管癌靶向及免疫治疗研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 53-59.
[12]	詹海峰, 谭子煊, 王文学, 耿嘉蔚.节律基因在结直肠癌发生发展和时辰疗法中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 60-64.
[13]	韦伟, 蔡曌颖, 钱亚云.通关藤联合XELOX方案促进人结直肠癌HCT116细胞双硫死亡的作用[J]. 国际肿瘤学杂志, 2024, 51(9): 545-555.
[14]	伍杨, 李甜, 张润兵, 史婷婷, 高春, 郑晓凤, 张久聪.胃癌及食管胃结合部癌免疫及靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 595-600.
[15]	詹海峰, 王文学, 耿嘉蔚.晚期结直肠癌精准分子靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 601-605.

KRASG12C抑制剂在晚期结直肠癌治疗中的研究进展

Research progress of KRASG12Cinhibitors in the treatment of advanced colorectal cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献39

相关文章15

编辑推荐

Metrics

本文评价

KRAS^G12C抑制剂在晚期结直肠癌治疗中的研究进展

Research progress of KRAS^G12Cinhibitors in the treatment of advanced colorectal cancer